Oncology

The development of the oncology drug pipeline originates fromthe mechanisms underlying the emergence of drug resistance in cancer cells, exploring novel strategies for designing anti-cancer drugs, and developing drug molecules that can either block the formation of resistance or eradicate drug-resistant cancer cells.

Virology

Currently, our virology pipeline focuses on the development of broad-spectrum small molecule drugs targeting coronaviruses, with indications encompassing diseases such as COVID-19 (Coronavirus Disease 2019), Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS), as well as other epidemic diseases.